Skip to content

Clinical study of Xingnaojing for the treatment of convulsive diseases

Clinical study of Xingnaojing for the treatment of convulsive diseases

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-08000097
Enrollment
Unknown
Registered
2008-05-06
Start date
2008-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Convulsive diseases

Interventions

Controlled group:Basical treatment without Xingnaojing
Treatment group:Xingnaojing 0.2-0.6ml/kg, +basical treatment

Sponsors

Shenzhen Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. Febrile convulsion: positive family history of febrile convulsion; aged between 6 months and 6 years old; in accordance with the diagnosis criteria of simple type of febrile convulsion; 2. Frequent episodes of epilepsy: epilepsy episodes of all types; > 3 times / week; 3. Refractory epilepsy: no satisfactory efficacy after treatment by 2~3 antiepileptic drugs; >=1 time/month; 4. Cerebral palsy: all types of cerebral palsy in children less than 3 years old.

Exclusion criteria

Exclusion criteria: 1. Febrile convulsion: family history of epilepsy, complex type of febrile convulsion, epileptic episodes, febrile convulsion plus; 2. Frequent episodes of epilepsy: combined with advanced diseases; 3. Refractory epilepsy: epilepsy combined with advanced diseases; 4. Cerebral palsy: advanced diseases combined with backwardness or retardation of brain function development.

Design outcomes

Primary

MeasureTime frame
Antipyretic rate;Frequency of convulsive episode;

Secondary

MeasureTime frame
Effective rate of treatment for cerebral palsy;Frequency of epileptic episode;

Countries

China

Contacts

Public ContactJianxiang Liao
liaojianxiang@sina.com+86 13602645027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026